Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772

PURPOSE: GSK2982772 is a selective inhibitor of receptor-interacting protein kinase-1, with a 2–3 h half-life. This study evaluated if a once-daily modified-release formulation of GSK2982772 could be developed with no significant food effect. METHODS: Part A evaluated the pharmacokinetics of GSK2982...

Descripción completa

Detalles Bibliográficos
Autores principales: Tompson, Debra J., Whitaker, Mark, Pan, Rennan, Johnson, Geoffrey, Fuller, Teresa, McKenzie, Litza, Zann, Vanessa, Powell, Marcy, Abbott-Banner, Kathy, Hawkins, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292240/
https://www.ncbi.nlm.nih.gov/pubmed/34136987
http://dx.doi.org/10.1007/s11095-021-03059-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292240/
https://www.ncbi.nlm.nih.gov/pubmed/34136987
http://dx.doi.org/10.1007/s11095-021-03059-z

Ejemplares similares